Mesoblast Limited vs Vertiv Holdings Co — how do they compare? Mesoblast Limited trades at $14.25 (market cap $1.75B), while Vertiv Holdings Co trades at $243.25 (market cap $93.83B). The key difference: Vertiv Holdings Co is far larger — about 53.6× Mesoblast Limited's market cap, and Vertiv Holdings Co pays a 0.1% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Vertiv Holdings Co for 39 Days on average.
| MESO | VRT | |
|---|---|---|
Market Cap | $1.75B | $93.83B |
Volume | 239,027 | 5,855,911 |
Sector | Health | Industrials |
52-Week High | $20.96 | $376.23 |
52-Week Low | $13.19 | $149.83 |
Typical Hold Time | 15 Days | 39 Days |
Enterprise Value | $1.83B | $94.06B |
Dividend Yield | — | 0.1% |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Vertiv (VRT) trades at $244.75, down 0.71% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $1.52 versus $1.42 expected, and robust profitability with a net income margin of 15.09% and ROE of 43.94%. Revenue growth is projected to increase from $10.23B in 2025 to $11.5B in 2026. Analyst sentiment remains overwhelmingly positive with a 95.24% buy rating and a consensus price target of $364.94, highlighting confidence in VRT's position in the AI data center infrastructure market.
The outlook for VRT is bullish based on strong earnings momentum and AI-driven demand for data center solutions, though high valuation ratios (P/E of 55.14) and a recent legal investigation pose risks. The stock offers significant upside to the consensus target, but investors should monitor competitive pressures and execution on growth forecasts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →